Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 50

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 50
---
-K for the fiscal year ended December 31, 2024. The value of the 2024 Executive PSUs, assuming achievement of the maximum performance level of 200%, would be: Mr. Peetz – $1,986,750; Mr. Bjerkholt – $529,800; Mr. Radovich – $913,905; and Dr. Quan – $529,800. As vesting is based on performance, it is uncertain whether our named executive officers will realize any value from the 2024 Executive PSUs.

(2) Amounts shown in this column do not reflect dollar amounts actually received by our named executive officers. Instead, these amounts reflect the aggregate grant date fair value of each stock option granted computed in accordance with the provisions of FASB ASC Topic 718. Assumptions used in the calculation of these amounts are included in Note 12, Stock-Based Compensation, to our consolidated financial statements included in the Annual Report. Our named executive officers will only realize compensation to the extent the trading price of our common stock is greater than the exercise price of such stock options.

(3) Amounts for 2024 represent bonuses awarded in January 2025 in recognition of 2024 performance, as more fully described in the section titled “Compensation Discussion and Analysis—2024 Executive Compensation Program—Bonus Compensation”.

(4) Amounts shown in this column represent matching payments under our 401(k) Plan, a qualified deferred compensation plan under Section 401(k) of the Code.

(5) Mr. Peetz previously served as our President from December 2018 to January 2024. In January 2024, Peter Radovich was appointed our President.

(6) Mr. Bjerkholt joined Mirum in September 2023.

(7) Mr. Radovich previously served as our Chief Operating Officer from April 2020 to January 2024, when he was appointed our President in addition to remaining our Chief Operating Officer.

(8) Dr. Quan joined Mirum in January 2024.

#### Mirum Pharmaceuticals2025 Proxy Statement41

#### TABLE OF CONTENTS

#### Executive Compensation

#### Grants of Plan-Based Awards
The following table shows certain information regarding grants of plan-based awards to the named executive officers for the fiscal year ended December 31, 2024:

|                    |     | Grant Date |        |     | Compensation  
 Committee     
 Approval Date |     |           | Estimated Future Payouts Under Non-Equity